In recent years, Dean Foods has been besieged by surging healthcare costs, with specialty drugs being a key cost driver. Not having expert knowledge about specialty drugs, the company, in some cases, had been unknowingly paying for the inappropriate utilization of these types of products. Rather than hoping its participation in a pharmacy benefit collective would throttle its rapidly increasing specialty spend, Dean Foods took the bull by the horns and chose to better manage and achieve higher value from this healthcare category.
CLICK to read:
https://www.viviohealth.com/wp-content/uploads/2020/08/VIVIO-Biosimilars-Case-Study-202008.pdf
